These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17239469)

  • 1. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals.
    Crisp MT; Tucker CJ; Rogers TL; Williams RO; Johnston KP
    J Control Release; 2007 Feb; 117(3):351-9. PubMed ID: 17239469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental determination of the diffusion boundary layer width of micron and submicron particles.
    Galli C
    Int J Pharm; 2006 Apr; 313(1-2):114-22. PubMed ID: 16529883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of surfactant on dissolution of spherical particles in micellar systems.
    Allaboun H; Alkhamis KA; Al Jbour ND
    Eur J Pharm Biopharm; 2007 Feb; 65(2):188-97. PubMed ID: 17027244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization.
    Matteucci ME; Hotze MA; Johnston KP; Williams RO
    Langmuir; 2006 Oct; 22(21):8951-9. PubMed ID: 17014140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs.
    Overhoff KA; Engstrom JD; Chen B; Scherzer BD; Milner TE; Johnston KP; Williams RO
    Eur J Pharm Biopharm; 2007 Jan; 65(1):57-67. PubMed ID: 16987642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanistic study of danazol dissolution in ionic surfactant solutions.
    Sun W; Larive CK; Southard MZ
    J Pharm Sci; 2003 Feb; 92(2):424-35. PubMed ID: 12532392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents.
    Kawakami K; Oda N; Miyoshi K; Funaki T; Ida Y
    Eur J Pharm Sci; 2006 May; 28(1-2):7-14. PubMed ID: 16406526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs.
    Lehto P; Kortejärvi H; Liimatainen A; Ojala K; Kangas H; Hirvonen J; Tanninen VP; Peltonen L
    Eur J Pharm Biopharm; 2011 Aug; 78(3):531-8. PubMed ID: 21329757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an oral rutin nanocrystal formulation.
    Mauludin R; Müller RH; Keck CM
    Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miniaturization of powder dissolution measurement and estimation of particle size.
    Avdeef A; Tsinman K; Tsinman O; Sun N; Voloboy D
    Chem Biodivers; 2009 Nov; 6(11):1796-811. PubMed ID: 19937817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media.
    Sunesen VH; Pedersen BL; Kristensen HG; Müllertz A
    Eur J Pharm Sci; 2005 Mar; 24(4):305-13. PubMed ID: 15734297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth.
    Lindfors L; Skantze P; Skantze U; Westergren J; Olsson U
    Langmuir; 2007 Sep; 23(19):9866-74. PubMed ID: 17696457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: Micronization of neat particles.
    Perrut M; Jung J; Leboeuf F
    Int J Pharm; 2005 Jan; 288(1):3-10. PubMed ID: 15607252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of molecular pathways in the micellar solubilization of monodisperse emulsion droplets.
    Ariyaprakai S; Dungan SR
    Langmuir; 2008 Apr; 24(7):3061-9. PubMed ID: 18324848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photoassisted tuning of silicon nanocrystal photoluminescence.
    Choi J; Wang NS; Reipa V
    Langmuir; 2007 Mar; 23(6):3388-94. PubMed ID: 17295527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity.
    Balakrishnan A; Rege BD; Amidon GL; Polli JE
    J Pharm Sci; 2004 Aug; 93(8):2064-75. PubMed ID: 15236455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of an active pharmaceutical ingredient by its dissolution properties: amoxicillin trihydrate as a model drug.
    Horkovics-Kovats S
    Chemotherapy; 2004 Nov; 50(5):234-44. PubMed ID: 15528889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant.
    Sheng JJ; Kasim NA; Chandrasekharan R; Amidon GL
    Eur J Pharm Sci; 2006 Nov; 29(3-4):306-14. PubMed ID: 16982177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution.
    Tinke AP; Vanhoutte K; De Maesschalck R; Verheyen S; De Winter H
    J Pharm Biomed Anal; 2005 Oct; 39(5):900-7. PubMed ID: 16023816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy.
    Mukherjee S; Ray S; Thakur RS
    Pak J Pharm Sci; 2009 Apr; 22(2):131-8. PubMed ID: 19339221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.